Home › Major Depressive Disorder › Maryland
Major Depressive Disorder clinical trials in Maryland
21 studies for Major Depressive Disorder are looking for participants at sites in Maryland.
Cities in Maryland
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 8 to 70 · All sexes · Updated Oct 2, 2026 · NCT05669703Natural History of Depression, Bipolar Disorder and Suicide Risk
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 1, 2026 · NCT06462196A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Oct 1, 2026 · NCT07573176Characterization and Treatment of Adolescent Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 11 to 25 · All sexes · Updated Sep 28, 2026 · NCT03388606A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Delricht Research - Rockville, Rockville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Sunstone Medical, PC, Rockville
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Sep 22, 2026 · NCT03065335Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- National Institutes of Health Clinical Center, Bethesda
- University of Maryland, College Park, College Park
RecruitingPhase 2Healthy volunteers welcome
Ages 8 to 65 · All sexes · Updated Sep 22, 2026 · NCT00018057Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Sep 14, 2026 · NCT06511908Defining Neurobiological Links Between Substance Use and Mental Illness
- National Institute on Drug Abuse, Baltimore
RecruitingHealthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Sep 11, 2026 · NCT05538910Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT03973268Neurobiology of Suicide
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT02543983A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Pharmasite Research Inc., Baltimore
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Gaithersburg
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Continental Clinical Solutions, Towson
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Gaithersburg
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Pikesville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Sheppard Pratt, Baltimore
- Sunstone Medical, PC, Rockville
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.